AstraZeneca
AZN
C$96.46
Share price
-1.98%
Change (1 day)
-9.71%
Change (1 year)
Categories
AstraZeneca (AZN) - Total debt
Total debt on the balance sheet as of March 2025 : C$42.92 Billion
According to AstraZeneca's latest financial reports the company's total debt is C$42.92 Billion. A company’s total debt is the sum of all current and non-current debts.
AstraZeneca - Total debt on balance sheet (from 1996 to 2025)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2024-12-31 | C$43.21 B | 13.83% |
| 2023-12-31 | C$37.96 B | -4.29% |
| 2022-12-31 | C$39.66 B | 1.12% |
| 2021-12-31 | C$39.22 B | 50.96% |
| 2020-12-31 | C$25.98 B | 9.16% |
| 2019-12-31 | C$23.80 B | -8.57% |
| 2018-12-31 | C$26.03 B | 16.29% |
| 2017-12-31 | C$22.38 B | -0.88% |
| 2016-12-31 | C$22.58 B | 8.17% |
| 2015-12-31 | C$20.88 B | 65.95% |
| 2014-12-31 | C$12.58 B | 13.92% |
| 2013-12-31 | C$11.04 B | 7.73% |
| 2012-12-31 | C$10.25 B | 8.05% |
| 2011-12-31 | C$9.48 B | 2.93% |
| 2010-12-31 | C$9.21 B | -20.81% |
| 2009-12-31 | C$11.64 B | 738.32% |
| 2008-12-31 | C$1.38 B | -90.82% |
| 2007-12-31 | C$15.11 B | 961.82% |
| 2006-12-31 | C$1.42 B | 1.84% |
| 2005-12-31 | C$1.39 B | -8.26% |
| 2004-12-31 | C$1.52 B | 158.24% |
| 2003-12-31 | C$0.59 B | -55.72% |
| 2002-12-31 | C$1.33 B | -12.47% |
| 2001-12-31 | C$1.52 B | 20.24% |
| 2000-12-31 | C$1.26 B | -21.52% |
| 1999-12-31 | C$1.61 B | -7.76% |
| 1998-12-31 | C$1.74 B | 4.48% |
| 1997-12-31 | C$1.67 B | -1.66% |
| 1996-12-31 | C$1.70 B |
Total debt for similar companies or competitors
| Company | Total debt/th> | differencediff. | Country |
|---|---|---|---|
 Bristol-Myers Squibb BMY | C$70.28 B | 63.73% | 🇺🇸 USA |
 Pfizer PFE | C$84.07 B | 95.86% | 🇺🇸 USA |
 Merck MRK | C$47.79 B | 11.34% | 🇺🇸 USA |
 GlaxoSmithKline GSK | C$32.66 B | -23.90% | 🇬🇧 UK |
 Sanofi SNY | C$31.23 B | -27.24% | 🇫🇷 France |
 Eli Lilly LLY | C$52.83 B | 23.08% | 🇺🇸 USA |
 Johnson & Johnson JNJ | C$71.67 B | 66.97% | 🇺🇸 USA |
 Abbott Laboratories ABT | C$18.16 B | -57.69% | 🇺🇸 USA |
 Biogen BIIB | C$9.08 B | -78.84% | 🇺🇸 USA |
 Novartis NVS | C$42.89 B | -0.08% | 🇨🇭 Switzerland |